Startseite
Kongressberichte 2017
59th ASH Annual Meeting and Exposition
Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Novel Agents and Upfront Approaches
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Novel Agents and Upfront Approaches
Brad S. Kahl, et al.
The authors of the study conclude:
In this Phase 1 study, Lonca-T has demonstrated encouraging single-agent anti-tumor activity and manageable toxicity in pts with R/R B-cell lineage NHL. One DLT has been reported and the MTD has not yet been reached. Evaluation in specific NHL subtypes is now warranted, and a dose expansion in pts with DLBCL is planned initially. Updated safety, tolerability, and efficacy results will be presented at the meeting.
Study sponsored by ADC Therapeutics. http://clinicaltrials.gov/show/NCT02669017
Mark Roschewski, et al.
The authors of the study conclude:
This multicenter study confirms that DA-EPOCH-R cures most adult patients with BL irrespective of HIV status. Low-risk BL is cured with 3 cycles of systemic therapy and no IT therapy is required. The outcome of protocol-defined HR pts compares favorably with more intensive regimens and can be used across all age groups. Patients with BM and/or CNS involvement are at highest risk of treatment failure, and early IT MTX for pts with BM involvement should be considered. Future studies that incorporate rational targeted agents to the DA-EPOCH-R backbone may further improve outcomes by addressing CNS disease and overcoming intrinsic treatment resistance.
Jason R. Westin, et al.
The authors of the study conclude:
The combination of Obinutuzumab, Lenalidomide, and CHOP is well tolerated, with no dose limiting toxicity encountered in the phase Ib trial, and efficacy is impressive in this single center single arm Phase Ib/II trial. Adverse events do not appear to be different than expected with standard RCHOP. Final results and correlative analyses will be presented at the ASH meeting
Rene-Olivier Casasnovas, et al.
The authors of the study conclude:
Obinutuzumab plus chemotherapy is not superior to rituximab plus chemotherapy delivered every 14 days in young DLBCL patients. Cell of origin data are currently investigated using nanostring technology and will be presented at the time of the meeting.
Jakub Svoboda, et al.
The authors of the study conclude:
BV in combination with R-CHP for CD30+ PMBL, DLBCL, and GZL is a highly active and well-tolerated outpatient regimen. Clinical outcomes utilizing BV in frontline for CD30+ B-cell lymphomas are encouraging and warrant further investigation, especially in pts with PMBL.
Peter Martin, et al.
The authors of the study conclude:
CC-486 combined with R-CHOP showed promising preliminary efficacy in pts with high-risk, previously untreated DLBCL or grade 3B FL. Results from this study identified a RP2D of 300 mg for future studies of CC-486 plus R-CHOP in DLBCL pts. Adverse events were generally consistent with the known safety profile of azacitidine and toxicities associated with R-CHOP. Correlative analyses showed pharmacodynamic activity, the majority related to anti-lymphoma immune regulation.